Samar Al-Behaisi
Follow
Get notifications in MyBN when activity occurs.
Samar Al-Behaisi
Chief Medical Officer, Vice President of Medical Affairs / Race Oncology
Dr Samar Al-Behaisi obtained her medical degree in Hungary and went on to complete a PhD, with a focus on clinical oncology and chemotherapy in oncology practice. She subsequently completed a degree in pharmaco-economics with a focus on reimbursement of orphan drugs.
Dr Al-Behaisi joined the pharmaceutical industry in 1996, working initially for two Hungarian pharmaceutical companies as a clinical trial manager and medical advisor, then worked in Hungary with Novartis as senior medical marketing manager for oncology, GSK as oncology medical advisor and Genzyme as oncology medical director.
Moving to Switzerland, she worked for five years at Takeda as oncology medical director for Europe and Canada where she was responsible for opinion-leader relationships, advisory boards and medical education programs, as well as pre-launch and launch activities for several oncology drugs. At Takeda, Dr Al-Behaisi was also responsible for handling, evaluating and approving doctor requests for oncology drugs under the company’s named patient program (NPP).
Dr Al-Behaisi joined the pharmaceutical industry in 1996, working initially for two Hungarian pharmaceutical companies as a clinical trial manager and medical advisor, then worked in Hungary with Novartis as senior medical marketing manager for oncology, GSK as oncology medical advisor and Genzyme as oncology medical director.
Moving to Switzerland, she worked for five years at Takeda as oncology medical director for Europe and Canada where she was responsible for opinion-leader relationships, advisory boards and medical education programs, as well as pre-launch and launch activities for several oncology drugs. At Takeda, Dr Al-Behaisi was also responsible for handling, evaluating and approving doctor requests for oncology drugs under the company’s named patient program (NPP).
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 723rd | Thomson Resources | 0% | -31% |
| 1382nd | Nagambie Resources | -44% | -18% |
| 1622nd | Race Oncology | -60% | 60% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 905th |  | Race Oncology | $3.1m |
| 1069th | | Security Matters | $318k |
| 1072nd | | Nagambie Resources | $293k |
| 1074th | | Thomson Resources | $290k |
| 1076th | | Analytica | $282k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| REMUNERATION UPDATE: Chief Medical Officer, Vice President of Medical Affairs, Race Oncology | 03 Nov 2020 |
